-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Oncternal Therapeutics Estimates Cash, Cash Equivalents Were $63.7M As Of Dec. 31, 2022

Benzinga · 01/06/2023 16:22

-SEC Filing